Franssen Bernardo, Tabrizian Parissa, Weinberg Alan, Romanoff Anya, Tuvin Daniel, Labow Daniel, Sarpel Umut
Division of Surgical Oncology, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ann Surg Oncol. 2015 May;22(5):1639-44. doi: 10.1245/s10434-014-4083-x. Epub 2014 Sep 13.
The purpose of this study is to assess the short-term morbidity and mortality in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) with diaphragmatic involvement.
All patients undergoing CRS/HIPEC at a tertiary care institution from April 2007 to October 2013 were retrospectively reviewed. Patients with diaphragmatic disease (Group 1) were compared to those who did not (Group 2). Univariate, propensity score analysis, and multivariate analysis were used to compare groups focusing on postoperative complications.
A total of 199 patients underwent CRS/HIPEC. Diagnoses included appendiceal/colorectal cancers (56 %), pseudomyxoma peritoneii (12 %), and gastric cancer (7 %). Group 1 was composed of 89 patients (44.7 %) with diaphragmatic involvement, of which 37.1 % underwent diaphragm stripping and 62.9 % required a full-thickness diaphragmatic resection. Group 1 had longer operative times (p = 0.009), increased transfusion requirements (p = 0.007), less optimal cytoreduction (p = 0.010), longer ICU stay (p = 0.003), and overall hospital stay (p = 0.039). Major complications were significantly higher in Group 1: 26 (29 %) versus 16 (15 %), p = 0.020. Rate of respiratory complications was not different between groups (G1: 14/26, 53.8 % and G2: 6/16, 37.5 %, p = NS). Ninety-day mortality was not significantly different. Diaphragmatic involvement (Estimate 1.235, SE 0.387, p = 0.017) was an independent predictor of 30-day morbidity in patients with <5 organs involved in cytoreduction.
Diaphragmatic involvement is associated with higher tumor burden and more complex operations. It is a strong independent predictor 30-day morbidity in patients with <5 organs involved in cytoreduction. However, perioperative mortality rates are not significantly different between the groups, suggesting that diaphragm stripping or resection is warranted in well-selected patients if it allows for complete cytoreduction.
本研究旨在评估接受细胞减灭术联合热灌注腹腔化疗(CRS/HIPEC)且伴有膈肌受累的患者的短期发病率和死亡率。
回顾性分析2007年4月至2013年10月在一家三级医疗机构接受CRS/HIPEC的所有患者。将伴有膈肌疾病的患者(第1组)与不伴有膈肌疾病的患者(第2组)进行比较。采用单因素分析、倾向评分分析和多因素分析来比较两组患者的术后并发症情况。
共有199例患者接受了CRS/HIPEC。诊断包括阑尾/结直肠癌(56%)、腹膜假黏液瘤(12%)和胃癌(7%)。第1组由89例(44.7%)伴有膈肌受累的患者组成,其中37.1%的患者接受了膈肌剥脱术,62.9%的患者需要进行膈肌全层切除术。第1组的手术时间更长(p = 0.009),输血需求增加(p = 0.007),细胞减灭效果欠佳(p = 0.010),重症监护病房(ICU)住院时间更长(p = 0.003),总体住院时间更长(p = 0.039)。第1组的主要并发症明显更多:26例(29%)对16例(15%),p = 0.020。两组之间的呼吸系统并发症发生率无差异(第1组:14/26,53.8%;第2组:6/16,37.5%,p = 无显著性差异)。90天死亡率无显著差异。膈肌受累(估计值1.235,标准误0.387,p = 0.017)是细胞减灭术中受累器官少于5个的患者30天发病率的独立预测因素。
膈肌受累与更高的肿瘤负荷和更复杂的手术相关。它是细胞减灭术中受累器官少于5个的患者30天发病率的强有力独立预测因素。然而,两组之间的围手术期死亡率无显著差异,这表明在精心挑选的患者中,如果膈肌剥脱或切除术能够实现完全的细胞减灭,则是合理的。